Successful treatment of a 93-year-old patient with hypoplastic acute monocytic leukemia using macrophage colony-stimulating factor.

Abstract

A 93-year-old patient with hypoplastic acute monocytic leukemia (AMoL) achieved a complete remission after macrophage colony-stimulating factor (M-CSF) therapy. Initially, the patient was treated with a low dose of cytarabine, but this treatment proved ineffective. M-CSF was administered for 14 days by drip intravenous infusion, 800 x 10(4) units per day. After a gradual decrease in the number of leukemic cells, a rapid increase in neutrophils was observed in the peripheral blood, and a bone marrow examination 22 days after discontinuation of M-CSF medication revealed a complete remission. These findings suggest that M-CSF may be useful in treating some elderly patients who have hypoplastic AMoL.

• Authors: A Watanabe, Y Kawachi, Y Sakamoto, K Ishikawa, T Nishihara, T Uchida, M Mori, K Setsu, N Indo
• Journal: Clinical therapeutics (Clin Ther) 1995 Jan-Feb Vol. 17 Issue 1 Pg. 74-81 ISSN: 0149-2918 [Print] United States
• PMID: 7758063 (Publication Type: Case Reports, Journal Article)

Chemical References

• Cytarabine
• Macrophage Colony-Stimulating Factor

Topics

• Aged
• Aged, 80 and over
• Cytarabine (therapeutic use)
• Humans
• Leukemia, Monocytic, Acute (pathology, therapy)
• Macrophage Colony-Stimulating Factor (therapeutic use)
• Male
• Remission Induction